American pharmaceutical company specializing in reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anesthesia; generates roughly one-third of revenues from the U.S. market.
相关临床试验
0
0 进行中
药物批准
14
批准总数
监管机构
1
监管机构数
成立时间
2021
暂无试验阶段数据
暂无试验数据
暂无试验数据
- Sun Pharmaceutical Industries, India's largest drugmaker, is evaluating the acquisition of US-based Organon for approximately $10 billion, marking what would be the largest cross-border pharmaceutical acquisition in Indian history. - The potential deal would give Sun Pharma significant access to women's health products and biosimilars, including Organon's top-selling contraceptive Nexplanon and a robust biosimilar pipeline worth $660 million in annual sales. - Organon, spun out from Merck in 2021 with $9.5 billion in inherited debt, has faced financial challenges and leadership changes, making it an attractive turnaround opportunity for Sun Pharma's proven acquisition strategy.
- The FDA has approved Organon's supplemental New Drug Application extending NEXPLANON contraceptive implant use from three to five years, with clinical trials showing zero pregnancies during the extended period. - The approval includes comprehensive data on women with varying BMI values, including 38.1% with BMI ≥30 kg/m², demonstrating efficacy across diverse patient populations. - A new Risk Evaluation and Mitigation Strategy (REMS) program will be implemented starting February 2026 to ensure proper provider training for insertion and removal procedures.
- Genentech and Roche obtained ex-parte orders from the Brussels Local Division to inspect Organon's manufacturing facilities in the Netherlands and Belgium for evidence of patent infringement related to their breast cancer drug Perjeta. - The dispute centers on patent EP 2238172 protecting pertuzumab, a $4.4 billion anti-HER2 antibody, with Organon planning to launch a biosimilar after receiving EMA marketing authorization. - The court authorized broad evidence collection with €200,000 penalties for non-compliance, marking a significant adoption of UPC evidence gathering tools by pharmaceutical companies. - This case represents the first major pharmaceutical patent enforcement action using UPC inspection procedures, previously utilized only for other industries like heavy machinery.
- Samsung Bioepis is exploring the acquisition of its U.S. sales partner Organon as part of a strategic shift from indirect to direct sales to capture higher profit margins and strengthen market control. - The company has already begun transitioning to direct sales in Europe, reclaiming commercialization rights for Byooviz from Biogen and now directly selling four products in the European market. - This strategic pivot comes as Samsung Bioepis faces intensifying biosimilar competition and seeks to maximize cash generation to fund its new drug development pipeline, including ADC candidates developed with partners like IntoCell. - The move aligns with broader industry trends as drug price-cut policies create opportunities for biosimilar companies while increasing competitive pressure in the global market.
- The FDA has approved Poherdy (pertuzumab-dpzb) as the first interchangeable biosimilar to Genentech's Perjeta, marking a significant milestone in HER2-positive breast cancer treatment accessibility. - Shanghai Henlius Biotech and Organon's biosimilar received approval for all the same indications as the reference drug, including metastatic, adjuvant, and neoadjuvant HER2-positive breast cancer settings. - The approval comes amid ongoing patent litigation from Genentech and declining Perjeta sales, which dropped from $4.3 billion in 2021 to $4.1 billion in 2024. - Organon will handle US commercialization following a $103 million licensing deal, while analysts predict Perjeta sales could fall to just $797 million by 2031.
- New sub-analysis data from Phase 3 ADORING trials demonstrate that VTAMA (tapinarof) cream achieved a 49.5% vIGA-AD response rate in children aged 2-17 without atopic comorbidities, compared to 14.8% with vehicle (p<0.0001). - Early improvements in skin clearance were observed as early as week 1 and sustained through week 8, with significant benefits in eczema severity, sleep quality, and itch control regardless of comorbidity status. - The treatment showed a favorable safety profile with most common adverse events including folliculitis (7.8%), upper respiratory tract infection (4.6%), and headache (3.7%) in the pediatric population. - VTAMA cream received FDA approval in December 2024 for topical treatment of atopic dermatitis in adults and pediatric patients 2 years and older, representing the largest pediatric dataset for the drug to date.
- Organon CEO Kevin Ali resigned following an internal investigation that revealed improper sales practices involving the contraceptive implant Nexplanon to US wholesalers between 2022 and 2025. - The investigation found that two US wholesalers were asked to purchase more Nexplanon than needed at quarter-end periods, a practice known as "channel stuffing" that artificially inflated revenue figures. - Joseph Morrissey, executive vice president and head of manufacturing and supply, was appointed interim CEO while the company implements enhanced controls and remediation efforts. - The improper sales practices represented less than 1% of consolidated revenue but helped the company meet guidance and external revenue expectations during the affected periods.
- A comprehensive review by Hebrew University professor Mayer Brezis reveals that finasteride, a widely prescribed hair loss medication, significantly increases the risk of depression, anxiety, and suicide across multiple global populations. - Eight major studies conducted between 2017 and 2023 consistently found that finasteride users were significantly more likely to develop mood disorders or suicidal thoughts compared to non-users, with evidence spanning the US, Sweden, Canada, and Israel. - The FDA first acknowledged depression as a side effect only in 2011, nearly fifteen years after approval, and added suicidality warnings in 2022, despite early warnings dating back to 2002. - Researchers estimate that hundreds of thousands of men worldwide may have suffered depression due to finasteride use, with hundreds potentially dying by suicide over the past two decades.
- Genentech filed the first BPCIA litigation against Shanghai Henlius Biotech and Organon on August 14, 2025, alleging infringement of 24 patents by their proposed pertuzumab biosimilar HLX11. - The lawsuit represents the first patent challenge for a pertuzumab biosimilar, with Henlius and Organon's aBLA being the only publicly announced application currently pending with the FDA. - Genentech asserted 24 of the 47 patents it had listed during the BPCIA patent dance, including 10 method of treatment patents and 10 manufacturing patents. - The litigation seeks injunctive relief to prevent commercialization of HLX11 and damages for alleged patent infringement under the BPCIA framework.
- Daré Bioscience announced positive interim safety and efficacy results from its Phase 3 trial of Ovaprene, an investigational monthly hormone-free intravaginal contraceptive. - The trial's independent Data Safety Monitoring Board recommended the study continue without modification after finding approximately 9% pregnancy rate, consistent with company expectations. - No serious safety concerns were identified, though 17% of participants discontinued due to vaginal odor, and participants reported they would likely use Ovaprene if available. - Bayer holds rights to commercialize the product in the U.S. following completion of the pivotal trial, with potential payments up to $310 million in milestones plus royalties.
